Costello Medical ISPOR Presentations

**ISPOR 17th Annual European Congress, November 2014, Amsterdam, The Netherlands**

**W5** Value-based Assessment for NICE: How to Do the Calculations  
Kusel J, Boysen M, Hatswell AJ, Shah K

**HS3** Impact of Morbidity in Populations of North London Clinical Commissioning Groups on Patient Admission Rates and GP Referrals  
Groom ZC, Burgon J, Eddowes LA, Wilson T, Kusel J

**QA1** Economic Orphans? The Prevalence of Child-specific Utilities in NICE Appraisals for Paediatric Indications  
Montgomery S, Hassan M, Kusel J

**NI2** Predicting the Impact of Value-based Assessment on Future NICE Appraisals  
Beale RC, Maruszczak M, Kusel J

**PGI17** A Cost of Care Model for Inflammatory Bowel Disease with a UK NHS Perspective  
Miles G, Leonard SA, Ghosh N, Premchand P

**PND49** Expected Value of Partial Perfect Information for the Disability Progression Efficacy of Teriflunomide and Fingolimod in the Treatment of Relapsing-remitting Multiple Sclerosis  
Maruszczak M, Kusel J, Adlard N

**PMH63** Antidepressant Use and Suicide Rate in England: The Geographic Divide  
Anderson R, Wilson T, Griffiths M

**PRM124** Discrete Event Simulation for the Cost-effectiveness Evaluation of PET-CT Scans in the Diagnosis of Conn’s Disease in Hypertensive Patients  
Maruszczak M, Stewart G, Kusel J, Brown MJ

**PRM28** Systematic Review and Critique of Health Economic Models of Relapsing-remitting Multiple Sclerosis in the UK  
Kusel J, Maruszczak M, Montgomery S, Allen F, Adlard N

**PCN260** Investigating the Use of Personalised Medicine in Cancer Trials – An Update  
Hamilton K, Wilson T

**ISPOR 6th Asia-Pacific Conference, September 2014, Beijing, China**

**IP2** Disinvestment in Asia-Pacific: How Can This Be Implemented in HTA and What Can Be Learnt from Europe?  
Brooks-Rooney C, Kamae I, Tan ST, Gutiérrez-Ibarluzea I

**QA2** An Analysis of New Health Technologies and Reimbursement Pricing Structure in Taiwan  
Stewart G, Brooks-Rooney C

**PCN13** Analysing the Effects of a Disinvestment Decision in Breast Cancer Screening Programmes in Asia-Pacific Countries: A Modelling Approach  
Agirrezaabal I, Bunting C, Brooks-Rooney C

**PCN39** The Differences Between Cancer Drug Approvals in Japan and the USA  
Anderson R, Brooks-Rooney C

**PDB9** Impact of Ethnicity on the Efficacy and Safety Outcomes of Anti-diabetes Drugs – Case Study of Liraglutide in Asian and Non-Asian Populations  

**PMS30** Closing the Gap: Reduced Delay to Drug Marketing Approval Between the West and Asia  
Hamilton KI, Eddowes LA, Brooks-Rooney C

**PIN33** The Differences Between Infectious & Parasitic Drug Approvals in Japan and the USA  
Anderson R, Brooks-Rooney C
**ISPOR 19th Annual International Meeting, May 2014, Montreal, Canada**

**HC2** The Impact of NICE’s End-Of-Life Threshold on the Availability of New Cancer Therapies in England and Wales
Stewart G, Eddowes L, Hamerslag L, Kusel J

**PHP27** An Update on How NICE Manage Off-Label Comparators
Kusel J, Steeves S, Maruszczak M, Pettit L, Wilson T, Taylor D

**PGI30** Patterns of Generic and Proprietary Prescribing of Proton Pump Inhibitors (PPIs) Over Time in England
Hamilton K, Kusel J, Leonard S

**PDB128** Insulin Pumps for the Treatment of Type 1 Diabetes Mellitus: Why is Uptake so Low in the UK?
Marsh W, Wilson T, Kusel J

**ISPOR 16th Annual European Congress, November 2013, Dublin, Ireland**

**IP13** Should Off-Label Agents Be Used as Comparators in Health Technology Assessments?
Kusel J, Walker W, Spackman E, Andersson C

**PCN207** Impact of Recommended Pharmaceuticals on Cancer Mortality: Analysis of Real-Life Data
Wilson T, Hamerslag L, Kusel J

**PHP152** The Relationship Between Scientific Research, Clinical Trials and FDA Drug Approval
Burgon J, Hamerslag L

**PHP166** How Does the Uncertainty Around the Expected ICER Affect NICE Decisions?
Barber R, Steeves S, Wilson T, Hamerslag L, Kusel J

**PMH68** How Well Do We Understand the Economic Burden Associated with Dementia? A Focus on Trends in Care Home Costs and Future Perspectives in the UK
Griffiths M, Hamerslag L, Wilson T, Stewart G, Kusel J

**PMS27** Global Variations in Biologics Access and Rheumatoid Arthritis Treatment Costs
Miles G, Bell J, Wilson T, Hamerslag L, Kusel J

**ISPOR 18th Annual International Meeting, May 2013, New Orleans, USA**

**PSY89** Treatment Options in Obesity: Is Clinical Development Keeping up with an Expanding Population?
Hay J, Barber R, Kusel J, Wilson T

**PMS48** Quality of Life in Rheumatoid Arthritis: How Much Do We Really Know?
Miles GA, Rolfe F, Kusel J, Brooks-Rooney C, Hay J

**PHP104** Assessing the Implementation of NICE Guidance: Is There a Correlation Between Recommendations and Uptake in Clinical Practice
NI2 The Use of Off-Label Comparators in NICE Appraisals – An Indirect Endorsement?
Kusel J, Wong GK, Hay JA, Pettit LJ

CA2 Applying a Value-Based Price Across Different Disease Areas
Wilson TJ, Kusel J, Brooks-Rooney C, Costello S

PCN144 Access to Cancer Interventions Across the UK: To What Extent Does SMC Advice Agree with NICE’s End-of-Life Therapies?
Hamerslag L, Brooks-Rooney C, Zhou A, Pettit L

HC4 Tapping into the Asian Pharmaceutical Market: Global Firms Go Local?

PHP82 The Characteristics of Clinical Trials in Asia
Brooks-Rooney C, Wong GKW, Hamerslag L, Costello S

PRM11 The Use of Biomarkers in Cancer Trials in Asia
Hamerslag L, Wilson T, Brooks-Rooney C

PCN148 The Use of Personalised Medicine in Cancer Trials

PHP66 Assessing Agreement Between Patient Access Schemes: Review of NICE and SMC Guidance
Timm B, Leonard S, Haynes S

PRM11 The Rise of Budget Impact Analyses – Another Hurdle in the Health Technology Approval Process?
Wong GKW, Hamer N, Wilson T, Costello S

Hamerslag L, Haynes S, Kusel J, Costello S

RS4 The Interim Cancer Drugs Fund – How To Not Spend £50 Million
Timm B, Brooks-Rooney C, Hamerslag L, Costello S

PHP123 To What Extent Does Advice From the SMC Agree with that Published by NICE?
Leonard SA, Brooks-Rooney C, Kusel J, Costello S

PHP145 The Burden of Evidence in the Pharmaceutical Appraisal Process

PHP152 The Administrative Burden of Patient Access Schemes in the Changing UK Healthcare System: A Follow Up Study

PRM9 What Guidance is Available for Budget Impact Analysis?
Kusel J, Leonard S, Wilson T, Costello S
ISPOR 16th Annual International Meeting, May 2011, Baltimore, MD, USA

PRM3 The Burden of Caregiving: Assessing the Status of Current Clinical Research
Hamer N, Costello S, Hamerslag L, Haynes S, Roper S

PHP5 Incentive-based Interventions – Rewarding Patients for Good Behaviour
Haynes S, Costello S, Brooks-Rooney C, Hamer N

PHP7 Developing Public Health Guidance - What are the Data Gaps? Review of the Gaps in the Evidence Identified by NICE in the UK
Kusel J, Hamer N, Roper S, Hamerslag L, Costello S

PHP43 The Influence of Patient Access Schemes on Appraisal Decisions by NICE in the UK

PHP89 The Implementation of Public Health Guidance: Preference for Clinical over Behavioural Interventions
Hamerslag L, Kusel J, Haynes S, Brooks-Rooney C, Costello S

PMS69 The Use of Mixed Treatment Comparisons in NICE Technology Appraisals

ISPOR 13th Annual European Congress, November 2010, Prague, Czech Republic

NI4 Do Patient Access Schemes Result in an Acceptable Administrative Burden?
Haynes S, Costello S, Brooks-Rooney C, Hamer N

PHP94 Is it Cost-Effective to Change the Behaviour of Healthcare Professionals?

PHP98 Cost-Effectiveness Methodologies of Strategies that Aim to Change the Behaviour of Healthcare Professionals

ISPOR 15th Annual International Meeting, May 2010, Atlanta, GA, USA

PHP79 Innovative Pricing Agreements in UK NICE Submissions
Costello S, Haynes S, Kusel J, Brooks-Rooney C, Hamer N